Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





Inbox: End of RHI. Start of RHI Magnesita: Buy


26.10.2017

Zugemailt von / gefunden bei: Baader Bank (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)

Every RHI shareholder gets one RHI Magnesita share for one former RHI share. The new ISIN is NL0012650360.

Baader conclusion

    We confirm our Buy rating. We like to highlight that our base calculation for our current target price of the new company is based on assumptions of an EPS of EUR 4. We also calculated the EPS with the highest possible amount of shares after the end of the transaction. We started with the combined RHI and Magnesita EBIT of 2016, added EUR 40mn growth EBIT and EUR 60mn net synergies to reach an EBIT of EUR 335mn after the integration. We excluded EUR 55mn net interest based on net debt a bit above EUR 1bn at an average coupon of 5.4% and a tax rate of 28%. At the current stage it seems that almost every part of that calculation is conservative. We calculated our target price with a P/E of 10 in 2019. The main peer company, Vesuvius, also listed at the LSE, is currently trading at a P/E of approximately 12 based on its 2019 consensus average.

    We see the main risk in the execution of the integration. This includes, for instance, the transfer of production from Europe to the U.S. including all newly required approvals and licenses and the closure of sites or the upgrading of others on time and on budget. Another risk might be that the management decides for new takeovers before they have shown a successful integration of Magnesita.

Facts & Analysis

    The trading of RHI at the stock exchange in Vienna ended on 25 October with a share price of EUR 35.90. 

    On 26 October RHI merges with Magnesita Refractories and changes the name to RHI Magnesita. RHI Magnesita increases the number of shares from 39,819,039 by 5mn to 44,819,039. Beside the 5mn shares, the major Magnesita shareholders receive EUR 117mn. RHI Magnesita will have a 50% plus one share stake in Magnesita after that transaction.

    On Friday 27 October, RHI Magnesita will start with its first trading day at the London stock exchange. If we calculate the last price in euro with GBP/EUR of 1.12, the share price of RHI Magnesita might start around a level of GBP 32 at the LSE. 

    There will be no 9-months report from RHI on 9 November as the company does not exist anymore. RHI Magnesita intends to give a trading update for the combined company on 13 November.  

    In the coming weeks RHL Magnesita will launch the mandatory offer for the remaining shareholders. They need to get another 2/3 of the outstanding shares to delist Magnesita in Brazil. The entire process might last until mid 2018. RHI guided for a possible to increase of capital by another up to 5 million shares to pay for the remaining outstanding shares. The remaining outstanding shareholders can decide to receive cash and shares, like the two major shareholder, or cash only. The decision how many additional new shares the company has to or will give into the market will be made at the end of the mandatory offer period, most likely in the second quarter 2018. Depending on the decision of the outstanding shareholder, cash or shares, and the management of RHI Magnesita to sell remaining shares at the market, the number of shares might reach approximately 50 million. We have used this “worst case” in our current calculation.

    The numbers on the left and the next side still refer to the former RHI. We will come out with new and consolidated figures after we got first details about the combined structure of the P&L and balance sheet.

RHI © Aussendung



Aktien auf dem Radar:Rosenbauer, EuroTeleSites AG, Strabag, Warimpex, Kapsch TrafficCom, Zumtobel, OMV, Österreichische Post, ATX, ATX Prime, ATX TR, Andritz, Erste Group, Uniqa, RBI, VIG, Mayr-Melnhof, Lenzing, DO&CO, Pierer Mobility, Porr, voestalpine, Austriacard Holdings AG, Marinomed Biotech, Gurktaler AG Stamm, Wienerberger, UBM, RHI Magnesita, Oberbank AG Stamm, Agrana, Amag.

(BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)

Random Partner #goboersewien

Croma
Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/goboersewien


Meistgelesen
>> mehr





PIR-Zeichnungsprodukte
Newsflow
>> mehr

Börse Social Club Board
>> mehr
    BSN Vola-Event Rheinmetall
    #gabb #1789

    Featured Partner Video

    Der ruhige Weltmeister

    Das Sporttagebuch mit Michael Knöppel - 14. Februar 2025 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
    Das Sporttagebuch mit Michael Knöppel - 1...

    Books josefchladek.com

    Vic Bakin
    Epitome
    2024
    Void

    Miyako Ishiuchi
    Yokosuka again 1980-1990 (石内 都)
    1998
    Sokyu-sha

    Miyako Ishiuchi
    Zessho, Yokosuka Story (石内 絶唱、横須賀ストーリ)
    1979
    Shashin Tsushin Sha

    Matthew Genitempo
    Jasper
    2018/2024
    Twin Palms Publishers

    Alexey Brodovitch
    Ballet (reprint)
    2024
    Little Steidl Verlag

    Inbox: End of RHI. Start of RHI Magnesita: Buy


    26.10.2017, 3742 Zeichen

    26.10.2017

    Zugemailt von / gefunden bei: Baader Bank (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)

    Every RHI shareholder gets one RHI Magnesita share for one former RHI share. The new ISIN is NL0012650360.

    Baader conclusion

        We confirm our Buy rating. We like to highlight that our base calculation for our current target price of the new company is based on assumptions of an EPS of EUR 4. We also calculated the EPS with the highest possible amount of shares after the end of the transaction. We started with the combined RHI and Magnesita EBIT of 2016, added EUR 40mn growth EBIT and EUR 60mn net synergies to reach an EBIT of EUR 335mn after the integration. We excluded EUR 55mn net interest based on net debt a bit above EUR 1bn at an average coupon of 5.4% and a tax rate of 28%. At the current stage it seems that almost every part of that calculation is conservative. We calculated our target price with a P/E of 10 in 2019. The main peer company, Vesuvius, also listed at the LSE, is currently trading at a P/E of approximately 12 based on its 2019 consensus average.

        We see the main risk in the execution of the integration. This includes, for instance, the transfer of production from Europe to the U.S. including all newly required approvals and licenses and the closure of sites or the upgrading of others on time and on budget. Another risk might be that the management decides for new takeovers before they have shown a successful integration of Magnesita.

    Facts & Analysis

        The trading of RHI at the stock exchange in Vienna ended on 25 October with a share price of EUR 35.90. 

        On 26 October RHI merges with Magnesita Refractories and changes the name to RHI Magnesita. RHI Magnesita increases the number of shares from 39,819,039 by 5mn to 44,819,039. Beside the 5mn shares, the major Magnesita shareholders receive EUR 117mn. RHI Magnesita will have a 50% plus one share stake in Magnesita after that transaction.

        On Friday 27 October, RHI Magnesita will start with its first trading day at the London stock exchange. If we calculate the last price in euro with GBP/EUR of 1.12, the share price of RHI Magnesita might start around a level of GBP 32 at the LSE. 

        There will be no 9-months report from RHI on 9 November as the company does not exist anymore. RHI Magnesita intends to give a trading update for the combined company on 13 November.  

        In the coming weeks RHL Magnesita will launch the mandatory offer for the remaining shareholders. They need to get another 2/3 of the outstanding shares to delist Magnesita in Brazil. The entire process might last until mid 2018. RHI guided for a possible to increase of capital by another up to 5 million shares to pay for the remaining outstanding shares. The remaining outstanding shareholders can decide to receive cash and shares, like the two major shareholder, or cash only. The decision how many additional new shares the company has to or will give into the market will be made at the end of the mandatory offer period, most likely in the second quarter 2018. Depending on the decision of the outstanding shareholder, cash or shares, and the management of RHI Magnesita to sell remaining shares at the market, the number of shares might reach approximately 50 million. We have used this “worst case” in our current calculation.

        The numbers on the left and the next side still refer to the former RHI. We will come out with new and consolidated figures after we got first details about the combined structure of the P&L and balance sheet.

    RHI © Aussendung





    BSN Podcasts
    Christian Drastil: Wiener Börse Plausch

    D&D Research Rendezvous #11: Was kommt nach dem jüngsten Kursfeuerwerk? Wie schaut es mit Bankensteuer und Standort aus?




     

    Bildnachweis

    1. RHI , (© Aussendung)   >> Öffnen auf photaq.com

    Aktien auf dem Radar:Rosenbauer, EuroTeleSites AG, Strabag, Warimpex, Kapsch TrafficCom, Zumtobel, OMV, Österreichische Post, ATX, ATX Prime, ATX TR, Andritz, Erste Group, Uniqa, RBI, VIG, Mayr-Melnhof, Lenzing, DO&CO, Pierer Mobility, Porr, voestalpine, Austriacard Holdings AG, Marinomed Biotech, Gurktaler AG Stamm, Wienerberger, UBM, RHI Magnesita, Oberbank AG Stamm, Agrana, Amag.


    Random Partner

    Croma
    Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.

    >> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


    RHI, (© Aussendung)


    Useletter

    Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

    Newsletter abonnieren

    Runplugged

    Infos über neue Financial Literacy Audio Files für die Runplugged App
    (kostenfrei downloaden über http://runplugged.com/spreadit)

    per Newsletter erhalten


    Meistgelesen
    >> mehr





    PIR-Zeichnungsprodukte
    Newsflow
    >> mehr

    Börse Social Club Board
    >> mehr
      BSN Vola-Event Rheinmetall
      #gabb #1789

      Featured Partner Video

      Der ruhige Weltmeister

      Das Sporttagebuch mit Michael Knöppel - 14. Februar 2025 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
      Das Sporttagebuch mit Michael Knöppel - 1...

      Books josefchladek.com

      Miyako Ishiuchi
      Yokosuka again 1980-1990 (石内 都)
      1998
      Sokyu-sha

      Ruth Lauer Manenti
      I Imagined It Empty
      2024
      RM

      Gytis Skudzinskas
      Print of Truth / Truth of Print
      2024
      Noroutine Books

      Meinrad Schade
      War Without War
      2015
      Scheidegger & Spiess

      Angela Boehm
      Minus Thirty
      2024
      Hartmann Projects